Biotech companies spend a lot of money. They spend it on research and development, clinical trials, and (if they are lucky) marketing and a salesforce. Bringing a new pharmaceutical or medical device to market is an expensive proposition.
Asked at a BBC London TV hustings whether he had succeeded in bringing Londoners with him on clean air and car travel, he says: ‘We will find out on May 2’
Toyota Motor said on Thursday its global sales and production hit record highs in the year ended March 31, supported by robust demand and the absence of semiconductor supply constraints it had to endure in recent years. Still, Toyota plans to delay the start of its electric vehicle (EV) production in the U.S. and trim domestic production to ensure product safety and quality after a series of scandals at its group firms, the Mid Japan Economist newspaper said. For the year ended March, Toyota said its parent-only global sales rose 7.3% to 10.31 million units year-on-year, surpassing the 10 million mark for the first time, while its output came to 9.97 million units, up 9.2% on the year.
Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency situations harnessing its proprietary needle-free auto-injectors technology platform ZENEO®, reports its audited financial results for the year ending December 31, 2023. These results are now available on the Company’s website. Key financial information as of December 31, 2023 Crossject’s financial results for the year ending December 31, 2023 have
HUHTAMÄKI OYJ INTERIM REPORT 25.4.2024 AT 8:30 EEST Q1 2024 in brief Net sales decreased 4% to EUR 1,004 million (EUR 1,047 million)Comparable net sales growth was -2% at Group levelReported EBIT was EUR 78 million (EUR 87 million); adjusted EBIT was EUR 99 million (EUR 92 million)Reported EPS was EUR 0.35 (EUR 0.47); adjusted EPS was EUR 0.55 (EUR 0.51)The impact of currency movements was EUR -17 million on the Group's net sales and EUR -2 million on EBIT Key figures EUR million Q1 2024 Q1 2023
SAINT-DOLAY, France, April 25, 2024--Regulatory News: Vinpai (ISIN: FR001400AXT1; ticker: ALVIN), the specialist in the design, manufacture and marketing of functional ingredients based on algae and plants for the food and cosmetics industry, today announces its revenue for the first quarter of 2024.
PARIS, April 25, 2024--Regulatory News: Getlink (Paris:GET):
PRESS RELEASE Neuilly-sur-Seine, France – April 25, 2024 Strong start to the year; 2024 outlook confirmed Q1 2024 Key figures1 Revenue of EUR 1,439.5 million in the first quarter of 2024, up 2.5% year-on-year and up 8.0% organicallyStrong organic growth from Industry +16.3%, Certification +13.7%, Marine & Offshore +13.6%, compared to the first quarter of 2023; growth of +6.1% for Consumer Products Services, +3.6% for Buildings & Infrastructure and +3.2% for Agri-food & CommoditiesThe scope effec
PARIS, April 25, 2024--Regulatory News: Axway (Euronext: AXW.PA) made a solid start to 2024 thanks to sustained sales activity, driven in particular by the Americas and Rest of Europe regions, which recorded important revenue growth. As large companies continue to accelerate their move to cloud infrastructures, Axway is benefiting from its optimized organization by regions and main products to accelerate new customer acquisition. Over the period, thanks to 3 large deals, the value of new custome
PARIS, April 25, 2024--Regulatory News: Pernod Ricard (Paris:RI):
TRAINERS' HOUSE GROUP, STOCK EXCHANGE RELEASE, 25 APRIL 2024 at 8:30 January-March 2024 in brief net sales EUR 2.3 million (EUR 2.8 million), change of -18.3 % compared to the corresponding period of the previous yearoperating result EUR 0.2 million (EUR 0.4 million), 7.3 % of net sales (14.5 %)cash flow from operations EUR 0.2 million (EUR 0.3 million)earnings per share EUR 0.08 (EUR 0.19) Key figures at the end of first quarter of 2024 cash and cash equivalents EUR 1.3 million (EUR 2.5 million
Submitted FDA De Novo application for ARC-EX® System Successfully raised EUR 20M in equity capital Announced positive top-line results from Up-LIFT pivotal study Forged partnership to provide rapid access to US Veterans Health Administration Continued to pioneer brain-computer interface therapies for SCI EINDHOVEN, The Netherlands, April 25, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore
Press Release Atos reports first quarter 2024 performance1 Q1 2024 Revenue €2,479m, down -2.6% organically Eviden down -3.9% organically, reflecting continued softness in Americas and the UKTech Foundations down -1.5% organically, reflecting lower scope of work with certain customers in Americas and Central Europe Order entry of €1.6bn for a book-to-bill of 64%, compared with 73% in prior year Eviden book-to-bill at 83%, compared with 79% in prior year, driven by stronger demand in High-Performa
Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS(1) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€13bn in 2024Pharma launches up 90.5% to €606 million, led by Nexviazyme and ALTUVIIIOVaccines sales up 5.6%, boosted by BeyfortusConsumer Healthcare (CHC) up 9.0%, benefiting from the Qunol acquisition in Physical and Mental Wellness and strong Digestive Wellness performa
BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company. Close of business 24 Apr 2024. Estimated NAV Euro Shares Sterling Shares Estimated NAV € 27.8646 £ 24.9546 Estimated MTD return 1.13 % 1.24 % Estimated YTD return 1.15 % 1.57 % Estimated ITD return 178.65 % 149.55 % NAV and returns are calculated net of management and performance fees Market information Euro Shares Amsterdam (A
BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company. Close of business 24 Apr 2024. Estimated NAV Euro Shares Sterling Shares Estimated NAV € 27.8646 £ 24.9546 Estimated MTD return 1.13 % 1.24 % Estimated YTD return 1.15 % 1.57 % Estimated ITD return 178.65 % 149.55 % NAV and returns are calculated net of management and performance fees Market information Euro Shares Amsterdam (A
Flow Traders Q1 2024 Trading Update Amsterdam, the Netherlands - Flow Traders Ltd. (Euronext: FLOW) announces its unaudited Q1 2024 trading update. Highlights Flow Traders recorded Net Trading Income of €127.1m and Total Income of €129.6m in Q124, compared to €72.7m and €74.3m, respectively, in Q423, and €110.5m for both in Q123. Flow Traders’ Value Traded increased 7% in Q124 when compared to last quarter and was flat when compared to the same period last year.Total Operating Expenses were €68.
The cybersecurity market was valued at USD 179.8 Billion in 2022 and is expected to reach USD 408.6 Billion by 2032 and is expected to have a CAGR of 8.6%.Fort Collins, Colorado, April 25, 2024 (GLOBE NEWSWIRE) -- Increasing Adoption of Artificial Intelligence and Machine Learning in Cybersecurity The cybersecurity industry includes products, services, and solutions for safeguarding digital systems, networks, and data against cyber threats such malware, ransomware, phishing attacks, and data bre
Anze Kopitar fired a wrist shot past Stuart Skinner’s glove and into the top corner on a breakaway to give the Los Angeles Kings a 5-4 victory over the Edmonton Oilers on Wednesday night in Game 2 of the first-round playoff series. Kopitar picked up the puck near the Edmonton blue line, moved in on Talbot and shot from the slot as Oilers defenseman Darnell Nurse dove to try to block the shot. Los Angeles rebounded from a 7-4 loss Monday night in the opener to send the series to Los Angeles tied 1-1.
The shopper was minding her own business when she spotted a man following another woman around the store taking photos of her.
The yen was pinned on the weaker side of 155 per dollar on Thursday as the Bank of Japan (BOJ) kicks off its two-day rate-setting meeting, leaving traders nervous as to whether Tokyo will intervene while policy deliberations are still underway. As the BOJ meets to discuss monetary policy, expectations are for the central bank to keep its short-term interest rate target unchanged at the conclusion of the meeting on Friday, following last month's landmark exit from negative rates. "We expect the BOJ meeting to deliver a marginally hawkish hold outcome," said Carl Ang, fixed income research analyst at MFS Investment Management.
Yahoo Finance